Literature DB >> 25044445

Intravenous antibiotic durations for common bacterial infections in children: when is enough enough?

Alan R Schroeder1, Shawn L Ralston.   

Abstract

Durations of intravenous antibiotic therapy for bacterial infections in hospitalized children sometimes extend well beyond clinical recovery and are often the primary determinants of length of stay. These durations, however, are not always based on solid evidence. Moreover, fixed durations are invariant to important individual factors. We review guidelines and the available evidence for durations of intravenous antibiotic therapy for meningitis, bacteremia, urinary tract infection, and osteomyelitis, conditions where intravenous antibiotics often extend beyond resolution of clinical symptoms. We propose a framework for the duration of therapy that is intended to serve as a guide when standards of care are either nonexistent, dated, conflicting, or contrary to evidence from published studies. This framework incorporates patient-centered factors such as severity of infection, response to therapy, ease of intravenous access, harms and costs of ongoing intravenous treatment, and family preferences.
© 2014 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25044445     DOI: 10.1002/jhm.2239

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  2 in total

1.  Tablet/Capsule Size Variation Among the Most Commonly Prescribed Medications for Children in the USA: Retrospective Review and Firsthand Pharmacy Audit.

Authors:  Laura Jacobsen; Kathy Riley; Brian Lee; Kathleen Bradford; Ravi Jhaveri
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

2.  Opportunities for Stewardship in the Transition From Intravenous to Enteral Antibiotics in Hospitalized Pediatric Patients.

Authors:  Jillian M Cotter; Matt Hall; Sonya Tang Girdwood; John R Stephens; Jessica L Markham; James C Gay; Samir S Shah
Journal:  J Hosp Med       Date:  2021-02       Impact factor: 2.960

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.